<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435614</url>
  </required_header>
  <id_info>
    <org_study_id>2018-4305</org_study_id>
    <nct_id>NCT03435614</nct_id>
  </id_info>
  <brief_title>Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults</brief_title>
  <acronym>SOWA-ICU</acronym>
  <official_title>Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marc M. Perreault</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mechanically ventilated critically ill adults may require prolonged administration of opioids&#xD;
      to facilitate ventilator support and maintain comfort. The prolonged use has been associated&#xD;
      with withdrawal symptoms upon rapid weaning in critically ill patients, known as the&#xD;
      opioid-associated withdrawal syndrome (OIWS). Such withdrawal symptoms are well described in&#xD;
      the paediatric population, however there is a lack of information in the adult population.&#xD;
      Currently there is no bedside tool to rapidly identify such patients. Recognition of&#xD;
      withdrawal symptoms is the basis for the development of an assessment tool to identify&#xD;
      patients with OIWS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        1. To identify specific signs and symptoms of OIWS in mechanically ventilated adult&#xD;
           intensive care unit (ICU) patients receiving at least 72 hours of regular opioids at the&#xD;
           Montreal General Hospital (MGH) and the Royal Victoria Hospital (RVH) from February to&#xD;
           October 2018.&#xD;
&#xD;
        2. To determine if a change in serum cortisol is associated with the presence of OIWS.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. Considering our first objective is purely descriptive, no hypothesis can be stated.&#xD;
&#xD;
        2. OIWS is associated with an increase in serum cortisol.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      A prospective multicentre observational study will be carried out in two&#xD;
      university-affiliated hospital ICUs (Montreal General Hospital and Royal Victoria Hospital).&#xD;
      All mechanically ventilated adult ICU patients receiving regular (continuous or intermittent)&#xD;
      opioids for more than 72 hours will be prospectively screened daily for withdrawal symptoms&#xD;
      once the opioid dose is reduced by 10% or more. From that moment, daily evaluation by a&#xD;
      physician using the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria&#xD;
      for opioid withdrawal will be conducted. Concomitantly, signs and symptoms of withdrawal will&#xD;
      be collected by an investigator blinded to the DSM-5 assessment. These assessments will&#xD;
      continue daily until the patient is transferred out of ICU or a maximum of 14 days and will&#xD;
      be repeated once more between day 1 and day 4 post-transfer out of ICU.&#xD;
&#xD;
      A serum cortisol will be drawn on the first day of dose reduction by 10% or more (baseline)&#xD;
      and will be repeated either after 72 hours or upon patient discharge from the ICU, whichever&#xD;
      one occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Criteria</measure>
    <time_frame>From first day of opioid dose reduction until transfer out of Intensive care unit (ICU) or a maximum of 14 days, including one further assessment post-ICU transfer</time_frame>
    <description>Percentage of daily assessments associated with each of the following signs and symptoms experienced by patients with and without OIWS (Restlessness (Richmond Agitation-Sedation scale = 1), Agitation (RASS &gt; 1), Anxiety, Hallucinations, Insomnia/sleep disturbance (&lt; 4 hours of continuous sleep), Mydriasis (Pupil diameter &gt; 2 mm) and systolic blood pressure (SBP) &gt; 140 mmHg. These assessments were performed once daily.&#xD;
Note that for the group of patients experiencing IWS, the data on signs and symptoms are limited to the assessment on the day that patients experienced OIWS.&#xD;
The signs and symptoms presented (Restlessness; Agitation; Anxiety, Hallucinations, Insomnia/sleep disturbance; mydriasis; SBP &gt; 140) were selected based on a &gt; 15 % absolute difference between both groups which was judged to be clinically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Cortisol Level</measure>
    <time_frame>Baseline cortisol on first day of opioid dose reduction and on day 3 post-dose reduction, or on day of transfer out of ICU if patient is transferred before day 3.</time_frame>
    <description>Cortisol level were drawn on the first day of opioid weaning and repeated 72 hours after onset of weaning</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">29</enrollment>
  <condition>Substance Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Critically ill patients</arm_group_label>
    <description>Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opioids</intervention_name>
    <description>Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.</description>
    <arm_group_label>Critically ill patients</arm_group_label>
    <other_name>Analgesics</other_name>
    <other_name>Narcotics</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Mechanically ventilated adult ICU patients receiving continuous or regular intermittent&#xD;
        opioids for more than 72 hours.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients requiring mechanical ventilation and receiving continuous or regular&#xD;
             intermittent opioids for at least 72 hours.&#xD;
&#xD;
          -  Weaning of at least 10% from previous stable opioid dose. A weaning episode is defined&#xD;
             as a â‰¥ 10% decrease in the total stable opioid dose received over 4 hours for opioid&#xD;
             infusions and over 12 hours for intermittent opioid administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient for whom consent cannot be obtained&#xD;
&#xD;
          -  Patient and/or family unable to communicate in French or English&#xD;
&#xD;
          -  Patient who is deaf without appropriate hearing aid&#xD;
&#xD;
          -  Imminent and predictable death (&lt; 72 hours) according to medical team&#xD;
&#xD;
          -  Severe brain injury, defined as Glasgow Coma Scale (GCS) score of 8 or less at ICU&#xD;
             admission&#xD;
&#xD;
          -  Moderate brain injury, defined as GCS between 9 and 12, with elevated intracranial&#xD;
             pressure (ICP &gt; 20 mmHg) which requires ICP monitoring and osmotherapy&#xD;
&#xD;
          -  Acute neurological condition (e.g. status epilepticus, encephalopathy, stroke). If the&#xD;
             acute neurological condition resolves within 72 hours, the patient may be included in&#xD;
             the study.&#xD;
&#xD;
          -  Substance abuse prior to ICU admission.&#xD;
&#xD;
               -  Chronic alcohol use defined as alcohol consumption of more than 2 drinks/day&#xD;
                  and/or more than 14 drinks/week for men and 9 drinks/week for women.&#xD;
&#xD;
               -  Chronic use of illicit drugs and amphetamines (except amphetamines taken for&#xD;
                  therapeutic purposes) defined as a consumption of at least 3 times per week.&#xD;
&#xD;
               -  Chronic use of opioids (e.g. transdermal fentanyl, methadone, hydromorphone,&#xD;
                  etc.) defined as a consumption of at least 3 times per week.&#xD;
&#xD;
          -  Readmission to the MGH or RVH ICU during the recruitment period (limit of one study&#xD;
             entry per patient)&#xD;
&#xD;
          -  Spinal cord injury above the lumbar region&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Soleil Delisle, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc M Perreault, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc-Alexandre Duceppe, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Chiu AW, Contreras S, Mehta S, Korman J, Perreault MM, Williamson DR, Burry LD. Iatrogenic Opioid Withdrawal in Critically Ill Patients: A Review of Assessment Tools and Management. Ann Pharmacother. 2017 Dec;51(12):1099-1111. doi: 10.1177/1060028017724538. Epub 2017 Aug 9. Review.</citation>
    <PMID>28793780</PMID>
  </reference>
  <reference>
    <citation>Wang PP, Huang E, Feng X, Bray CA, Perreault MM, Rico P, Bellemare P, Murgoi P, GÃ©linas C, Lecavalier A, Jayaraman D, Frenette AJ, Williamson D. Opioid-associated iatrogenic withdrawal in critically ill adult patients: a multicenter prospective observational study. Ann Intensive Care. 2017 Sep 2;7(1):88. doi: 10.1186/s13613-017-0310-5.</citation>
    <PMID>28866754</PMID>
  </reference>
  <reference>
    <citation>Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998 Apr;26(4):676-84.</citation>
    <PMID>9559604</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <results_first_submitted>August 31, 2020</results_first_submitted>
  <results_first_submitted_qc>January 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2021</results_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Marc M. Perreault</investigator_full_name>
    <investigator_title>Pharmacist</investigator_title>
  </responsible_party>
  <keyword>Opioid</keyword>
  <keyword>Withdrawal</keyword>
  <keyword>Critically ill adults</keyword>
  <keyword>Cortisol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Narcotics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03435614/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Iatrogenic Withdrawal Syndrome (IWS) Positive</title>
          <description>Group of patients displaying signs and symptoms of IWS</description>
        </group>
        <group group_id="P2">
          <title>Iatrogenic Withdrawal Syndrome (IWS) Negative</title>
          <description>Group of patients not displaying signs and symptoms of IWS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1128 patients screened; 59 eligible as per entry criteria; 29 enrolled and included in the analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Opioid Iatrogenic WIthdrawal Syndrome (OIWS) Positive Patients</title>
          <description>Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours whose at least one daily DSM-5 assessment for OIWS was positive following the reduction in opioid dose (opioid dose reduction of 10% or greater).</description>
        </group>
        <group group_id="B2">
          <title>Opioid Iatrogenic Withdrawal Syndrome (OIWS) Negative Patients</title>
          <description>Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours whose daily DSM-5 assessments for OIWS remained negative for the duration of follow up following the reduction in opioid dose (opioid dose reduction of 10% or greater).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="62.0" upper_limit="77.3"/>
                    <measurement group_id="B2" value="64" lower_limit="44.0" upper_limit="74.0"/>
                    <measurement group_id="B3" value="65" lower_limit="47.5" upper_limit="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MIddle Eastern</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine at ICU admission (umol/L)</title>
          <units>umol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124" lower_limit="78" upper_limit="307"/>
                    <measurement group_id="B2" value="136" lower_limit="71" upper_limit="223"/>
                    <measurement group_id="B3" value="132" lower_limit="74" upper_limit="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reason for ICU admission (ICD-10)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Diseases of the circulatory system</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>External causes of morbidity and mortality (trauma)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Infectious and parasitic diseases</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Diseases of the digestive system</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Diseases of the respiratory system</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length of ICU stay</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.5" lower_limit="9.5" upper_limit="38.0"/>
                    <measurement group_id="B2" value="16" lower_limit="9.0" upper_limit="34.0"/>
                    <measurement group_id="B3" value="16.0" lower_limit="9.0" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of mechanical ventilation</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" lower_limit="7.3" upper_limit="37.3"/>
                    <measurement group_id="B2" value="9.0" lower_limit="5.0" upper_limit="26.0"/>
                    <measurement group_id="B3" value="9.0" lower_limit="5.5" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Co-morbidities</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary artery disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic kidney disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic obstructive pulmonary disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>As needed use of opioids prior to ICU admission</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of benzodiazepines prior to ICU admission</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Criteria</title>
        <description>Percentage of daily assessments associated with each of the following signs and symptoms experienced by patients with and without OIWS (Restlessness (Richmond Agitation-Sedation scale = 1), Agitation (RASS &gt; 1), Anxiety, Hallucinations, Insomnia/sleep disturbance (&lt; 4 hours of continuous sleep), Mydriasis (Pupil diameter &gt; 2 mm) and systolic blood pressure (SBP) &gt; 140 mmHg. These assessments were performed once daily.&#xD;
Note that for the group of patients experiencing IWS, the data on signs and symptoms are limited to the assessment on the day that patients experienced OIWS.&#xD;
The signs and symptoms presented (Restlessness; Agitation; Anxiety, Hallucinations, Insomnia/sleep disturbance; mydriasis; SBP &gt; 140) were selected based on a &gt; 15 % absolute difference between both groups which was judged to be clinically significant.</description>
        <time_frame>From first day of opioid dose reduction until transfer out of Intensive care unit (ICU) or a maximum of 14 days, including one further assessment post-ICU transfer</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IWS Positive</title>
            <description>Group of patients with OIWS positive as per DSM-V criteria</description>
          </group>
          <group group_id="O2">
            <title>IWS Negative</title>
            <description>Group of patients without OIWS as per DSM-V criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Criteria</title>
          <description>Percentage of daily assessments associated with each of the following signs and symptoms experienced by patients with and without OIWS (Restlessness (Richmond Agitation-Sedation scale = 1), Agitation (RASS &gt; 1), Anxiety, Hallucinations, Insomnia/sleep disturbance (&lt; 4 hours of continuous sleep), Mydriasis (Pupil diameter &gt; 2 mm) and systolic blood pressure (SBP) &gt; 140 mmHg. These assessments were performed once daily.&#xD;
Note that for the group of patients experiencing IWS, the data on signs and symptoms are limited to the assessment on the day that patients experienced OIWS.&#xD;
The signs and symptoms presented (Restlessness; Agitation; Anxiety, Hallucinations, Insomnia/sleep disturbance; mydriasis; SBP &gt; 140) were selected based on a &gt; 15 % absolute difference between both groups which was judged to be clinically significant.</description>
          <units>percentage of assessments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Restlessness (RASS = 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation (RASS &gt; 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucinations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia/Sleep disturbance (&lt; 4 hours of continuous sleep)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mydriasis (pupil size &gt; 2mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure (SBP) &gt; 140 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>We selected the individual signs and symptoms associated with the presence of OIWS based on a difference of greater than 15 % in the assessments between the group with OIWS and the group not displaying OIWS. This 15 % difference was judged to be of clinical significance.&#xD;
No data on cortisol values can be presented as too many cortisol samples could not be obtained prior to patient transferring out of ICU.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Cortisol Level</title>
        <description>Cortisol level were drawn on the first day of opioid weaning and repeated 72 hours after onset of weaning</description>
        <time_frame>Baseline cortisol on first day of opioid dose reduction and on day 3 post-dose reduction, or on day of transfer out of ICU if patient is transferred before day 3.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Symptom assessments were collected daily until transfer out of ICU, death or 14 days after start of patient remained in ICU; If patient was transferred, one additional data was collected up to 96 hours post-transfer out of ICU</time_frame>
      <desc>Observational study of IWS - Non interventional</desc>
      <group_list>
        <group group_id="E1">
          <title>Critically Ill Patients</title>
          <description>Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.&#xD;
Opioids: Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc Perreault</name_or_title>
      <organization>MUHC-RIMUHC</organization>
      <phone>514-343-6111 ext 3788</phone>
      <email>marc.perreault@umontreal.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

